financetom
Business
financetom
/
Business
/
EU 'wants level playing field', but still negotiating with China on car tariffs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EU 'wants level playing field', but still negotiating with China on car tariffs
Oct 17, 2024 2:43 PM

BERLIN, Oct 14 (Reuters) - The European Union wants a

level playing field with China on car tariffs and is negotiating

with Beijing on mechanisms such as price commitments or

investments in Europe as a solution, European Commission chief

Ursula von der Leyen said on Monday.

Speaking alongside German Chancellor Olaf Scholz in Berlin,

she said negotiations with China would continue even if the EU's

tariffs on Chinese electric vehicles entered into force. Scholz

expressed hope of reaching an agreement by the end of October.

"What could be the compensation that is offered instead of

countervailing duties, for example? And there is the question of

price commitments that are on the table, investments in Europe,"

von der Leyen said. "These are all questions that are on the

table, as always in negotiations. Everything has only been

negotiated when the last piece has been negotiated."

The two leaders met in Berlin as the EU prepares to impose

hefty import tariffs on Chinese-made electric vehicles, measures

that Germany and its car industry oppose, fearing retaliatory

measures in the vast Chinese market.

They were speaking on the same day as Chinese and European

automakers went head-to-head at the Paris car show, where

Chinese EV giant BYD warned the EU's planned tariffs

would only lead to higher prices and deter buyers.

Earlier this month, EU member states narrowly backed import

duties on Chinese-made EVs of up to 45%, meant to counter what

the European Commission says are unfair subsidies from Beijing

to Chinese manufacturers. Beijing denies unfair competition and

has threatened counter-measures.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved